Connection

CHRISTIE BALLANTYNE to Middle Aged

This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Middle Aged.
Connection Strength

6.102
  1. The impact of genetic testing on physician practice in specialized cardiovascular clinics. J Clin Lipidol. 2026 Mar; 20(3):677-681.
    View in: PubMed
    Score: 0.060
  2. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA. 2026 01 13; 335(2):129-139.
    View in: PubMed
    Score: 0.060
  3. Lipoprotein(a) and Risk of Incident Atherosclerotic Cardiovascular Disease: Impact of High-Sensitivity C-Reactive Protein and Risk Variability Among Human Clinical Subgroups. Nutrients. 2025 Apr 11; 17(8).
    View in: PubMed
    Score: 0.057
  4. Epidemiology and longitudinal course of chylomicronemia: Insights from NHANES and a large health care system. J Clin Lipidol. 2025 May-Jun; 19(3):432-441.
    View in: PubMed
    Score: 0.057
  5. Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and?Number?in?Hypertriglyceridemia. J Am Coll Cardiol. 2025 May 20; 85(19):1839-1854.
    View in: PubMed
    Score: 0.056
  6. Lipoprotein(a) levels in a population with clinical atherosclerotic cardiovascular disease in the United States: A subanalysis from the Lp(a)HERITAGE study. J Clin Lipidol. 2025 Jan-Feb; 19(1):28-38.
    View in: PubMed
    Score: 0.055
  7. Intensive Lifestyle Intervention, Cardiac?Biomarkers, and Cardiovascular?Outcomes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary Study. J Am Coll Cardiol. 2025 Feb 11; 85(5):489-500.
    View in: PubMed
    Score: 0.055
  8. Atrial Fibrillation and Clonal Hematopoiesis in TET2 and ASXL1. JAMA Cardiol. 2024 Jun 01; 9(6):497-506.
    View in: PubMed
    Score: 0.053
  9. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med. 2024 09 12; 391(10):899-912.
    View in: PubMed
    Score: 0.053
  10. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.
    View in: PubMed
    Score: 0.050
  11. Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J Am Coll Cardiol. 2023 04 25; 81(16):1553-1564.
    View in: PubMed
    Score: 0.049
  12. Atherosclerotic cardiovascular disease risk and small dense low-density lipoprotein cholesterol in men, women, African Americans and non-African Americans: The pooling project. Atherosclerosis. 2023 02; 367:15-23.
    View in: PubMed
    Score: 0.049
  13. Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2022 06; 350:82-89.
    View in: PubMed
    Score: 0.046
  14. Plasma Dehydroepiandrosterone Sulfate and Cardiovascular Disease Risk in Older Men and Women. J Clin Endocrinol Metab. 2020 12 01; 105(12).
    View in: PubMed
    Score: 0.042
  15. Levels and Change in Galectin-3 and Association With Cardiovascular Events: The ARIC Study. J Am Heart Assoc. 2020 07 07; 9(13):e015405.
    View in: PubMed
    Score: 0.041
  16. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020 04; 27(6):593-603.
    View in: PubMed
    Score: 0.038
  17. High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study. Circulation. 2019 06 04; 139(23):2642-2653.
    View in: PubMed
    Score: 0.038
  18. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 01 03; 380(1):11-22.
    View in: PubMed
    Score: 0.036
  19. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2019 01; 280:109-117.
    View in: PubMed
    Score: 0.036
  20. Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism. J Thromb Haemost. 2018 10; 16(10):1964-1972.
    View in: PubMed
    Score: 0.036
  21. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018 10; 277:195-203.
    View in: PubMed
    Score: 0.035
  22. Plasma Galectin-3 and Sonographic Measures of Carotid Atherosclerosis in the Atherosclerosis Risk in Communities Study. Angiology. 2019 Jan; 70(1):47-55.
    View in: PubMed
    Score: 0.035
  23. Improving Outcomes After Myocardial Infarction in the US Population. J Am Heart Assoc. 2018 02 17; 7(4).
    View in: PubMed
    Score: 0.035
  24. Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC). Atherosclerosis. 2018 01; 268:12-18.
    View in: PubMed
    Score: 0.034
  25. The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study. Atherosclerosis. 2017 07; 262:131-137.
    View in: PubMed
    Score: 0.033
  26. Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. Circulation. 2017 06 20; 135(25):2572-2574.
    View in: PubMed
    Score: 0.033
  27. A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol. 2017 Aug 15; 120(4):569-576.
    View in: PubMed
    Score: 0.033
  28. Looking Back at Look AHEAD Through the Lens of Recent Diabetes Outcome Trials. Circulation. 2017 02 21; 135(8):720-723.
    View in: PubMed
    Score: 0.032
  29. 25-Hydroxyvitamin D Levels and Markers of Subclinical Myocardial Damage and Wall Stress: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2016 11 07; 5(11).
    View in: PubMed
    Score: 0.032
  30. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol. 2017 Feb 01; 119(3):388-396.
    View in: PubMed
    Score: 0.032
  31. Postprandial Monocyte Activation in Individuals With Metabolic Syndrome. J Clin Endocrinol Metab. 2016 11; 101(11):4195-4204.
    View in: PubMed
    Score: 0.031
  32. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis. 2016 10; 253:81-87.
    View in: PubMed
    Score: 0.031
  33. Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites. J Am Heart Assoc. 2016 05 13; 5(5).
    View in: PubMed
    Score: 0.031
  34. Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy. Am J Cardiol. 2016 Jun 15; 117(12):1928-33.
    View in: PubMed
    Score: 0.030
  35. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2016 May-Jun; 10(3):635-645.e1.
    View in: PubMed
    Score: 0.030
  36. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016 May-Jun; 10(3):556-67.
    View in: PubMed
    Score: 0.030
  37. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. Am J Med. 2015 Nov; 128(11):1253-6.
    View in: PubMed
    Score: 0.029
  38. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015 May 01; 115(9):1212-21.
    View in: PubMed
    Score: 0.028
  39. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). J Clin Lipidol. 2015 May-Jun; 9(3):377-83.
    View in: PubMed
    Score: 0.028
  40. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014 May; 34(5):1069-77.
    View in: PubMed
    Score: 0.026
  41. Troponin T, NT-proBNP, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Vasc Med. 2014 Feb; 19(1):33-41.
    View in: PubMed
    Score: 0.026
  42. Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study. Clin Chem. 2013 Dec; 59(12):1802-10.
    View in: PubMed
    Score: 0.025
  43. Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study. Circ Heart Fail. 2013 Sep 01; 6(5):936-43.
    View in: PubMed
    Score: 0.025
  44. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24; 62(13):1154-62.
    View in: PubMed
    Score: 0.025
  45. Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study. Stroke. 2013 Jul; 44(7):1803-8.
    View in: PubMed
    Score: 0.025
  46. Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study. Stroke. 2013 Apr; 44(4):961-7.
    View in: PubMed
    Score: 0.025
  47. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial). Am J Cardiol. 2013 Feb 15; 111(4):506-9.
    View in: PubMed
    Score: 0.024
  48. Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players. Atherosclerosis. 2012 Jun; 222(2):551-6.
    View in: PubMed
    Score: 0.023
  49. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J. 2012 Mar; 163(3):515-21, 521.e1-3.
    View in: PubMed
    Score: 0.023
  50. Chromosome 9p21 single nucleotide polymorphisms are not associated with recurrent myocardial infarction in patients with established coronary artery disease. Circ J. 2012; 76(4):950-6.
    View in: PubMed
    Score: 0.023
  51. Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia. J Clin Lipidol. 2012 May-Jun; 6(3):235-43.
    View in: PubMed
    Score: 0.022
  52. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012 Jan 17; 125(2):241-9.
    View in: PubMed
    Score: 0.022
  53. Barriers to non-HDL cholesterol goal attainment by providers. Am J Med. 2011 Sep; 124(9):876-80.e2.
    View in: PubMed
    Score: 0.022
  54. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (= 2 mg/L). cmb@bcm.tmc.edu. J Clin Lipidol. 2011 Sep-Oct; 5(5):401-7.
    View in: PubMed
    Score: 0.022
  55. Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. Eur Heart J. 2012 Jan; 33(2):183-90.
    View in: PubMed
    Score: 0.022
  56. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011 Apr 05; 123(13):1367-76.
    View in: PubMed
    Score: 0.021
  57. Usefulness of single nucleotide polymorphism in chromosome 4q25 to predict in-hospital and long-term development of atrial fibrillation and survival in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2011 May 15; 107(10):1504-9.
    View in: PubMed
    Score: 0.021
  58. Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Cardiovasc Drugs Ther. 2011 Feb; 25(1):59-67.
    View in: PubMed
    Score: 0.021
  59. Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study. Eur Heart J. 2011 Feb; 32(4):459-68.
    View in: PubMed
    Score: 0.021
  60. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. 2010 Apr 13; 55(15):1600-7.
    View in: PubMed
    Score: 0.020
  61. Preoperative statin therapy decreases risk of postoperative renal insufficiency. Cardiovasc Ther. 2010 Apr; 28(2):80-6.
    View in: PubMed
    Score: 0.020
  62. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2009 Dec 15; 54(25):2388-95.
    View in: PubMed
    Score: 0.020
  63. Obesity: an independent predictor of in-hospital postoperative renal insufficiency among patients undergoing cardiac surgery? Tex Heart Inst J. 2009; 36(6):540-5.
    View in: PubMed
    Score: 0.018
  64. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009 Feb; 40(2):376-81.
    View in: PubMed
    Score: 0.018
  65. Does preoperative statin therapy improve outcomes in patients undergoing isolated cardiac valve surgery? Am J Cardiol. 2008 Nov 01; 102(9):1235-9.
    View in: PubMed
    Score: 0.018
  66. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol. 2008 Aug 19; 52(8):626-32.
    View in: PubMed
    Score: 0.018
  67. Prevalence of metabolic syndrome and associated risk factors in Asian Indians. J Immigr Minor Health. 2008 Aug; 10(4):313-23.
    View in: PubMed
    Score: 0.018
  68. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008 May 15; 101(10):1428-36.
    View in: PubMed
    Score: 0.018
  69. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008 May 13; 117(19):2458-66.
    View in: PubMed
    Score: 0.017
  70. Low-density lipoprotein and high-density lipoprotein cholesterol levels in relation to genetic polymorphisms and menopausal status: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2008 Oct; 200(2):322-8.
    View in: PubMed
    Score: 0.017
  71. Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study. Tex Heart Inst J. 2008; 35(4):388-94.
    View in: PubMed
    Score: 0.017
  72. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008 Mar 01; 101(5):625-30.
    View in: PubMed
    Score: 0.017
  73. How to identify patients with vulnerable plaques. Diabetes Obes Metab. 2008 Sep; 10(10):824-33.
    View in: PubMed
    Score: 0.017
  74. Increasing prevalence of obesity and clustered cardiometabolic risk: can treatment of the underlying cause reverse the trends? Crit Pathw Cardiol. 2007 Jun; 6(2):41-5.
    View in: PubMed
    Score: 0.016
  75. Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care. 2007 Feb; 30(2):325-31.
    View in: PubMed
    Score: 0.016
  76. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007 Mar 01; 99(5):673-80.
    View in: PubMed
    Score: 0.016
  77. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J. 2006 May; 151(5):975.e1-9.
    View in: PubMed
    Score: 0.015
  78. Prediabetes, Subclinical Myocardial Injury or Stress, and Heart Failure Risk for Adults With Hypertension. JAMA Cardiol. 2026 Mar 01; 11(3):281-287.
    View in: PubMed
    Score: 0.015
  79. Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026 Mar; 32(3):1052-1060.
    View in: PubMed
    Score: 0.015
  80. Proteomic Signatures of Cardiac Dysfunction Among People With Diabetes: The Atherosclerosis Risk in Communities Study. Circ Heart Fail. 2026 Mar; 19(3):e013171.
    View in: PubMed
    Score: 0.015
  81. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2026 Feb; 14(2):123-136.
    View in: PubMed
    Score: 0.015
  82. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005 Nov 28; 165(21):2479-84.
    View in: PubMed
    Score: 0.015
  83. Human plasma proteomic profile of clonal hematopoiesis. Nat Commun. 2025 Nov 27; 16(1):11688.
    View in: PubMed
    Score: 0.015
  84. Predicted Risk, Preclinical Heart Failure Measures, and Incident Heart Failure: The ARIC Study. JACC Heart Fail. 2025 Nov; 13(11):102659.
    View in: PubMed
    Score: 0.015
  85. A Metabolomics Study of Cardiac Dysfunction in Hyperglycemia: Findings From the Atherosclerosis Risk in Communities (ARIC) Study and the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Diabetes Care. 2025 Sep 01; 48(9):1589-1597.
    View in: PubMed
    Score: 0.015
  86. Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
    View in: PubMed
    Score: 0.015
  87. Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis. Atherosclerosis. 2025 Oct; 409:120447.
    View in: PubMed
    Score: 0.015
  88. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005 Aug 15; 96(4):556-63.
    View in: PubMed
    Score: 0.015
  89. Adipokines and Transitions in Metabolic Health Over Time: The Atherosclerosis Risk In Communities (ARIC) Study. J Clin Endocrinol Metab. 2025 Aug 07; 110(9):e2939-e2945.
    View in: PubMed
    Score: 0.015
  90. Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics. Am Heart J. 2025 Dec; 290:325-338.
    View in: PubMed
    Score: 0.014
  91. Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system. Clin Chem. 2005 Jul; 51(7):1102-9.
    View in: PubMed
    Score: 0.014
  92. Multi-ancestry genome-wide association analyses incorporating SNP-by-psychosocial interactions identify novel loci for serum lipids. Transl Psychiatry. 2025 Jun 20; 15(1):207.
    View in: PubMed
    Score: 0.014
  93. A Meta-Analysis and Systematic Review of Cardiac Troponin I vs T in Community Dwelling Adults: Is Specificity at Risk? Clin Chem. 2025 Jun 03; 71(6):664-676.
    View in: PubMed
    Score: 0.014
  94. Lipoprotein(a) and Heart Failure Among Black and White Participants in Atherosclerosis Risk in Communities Study, Framingham Offspring Study, and Multi-Ethnic Study of Atherosclerosis: The Pooling Project. J Am Heart Assoc. 2025 Jun 03; 14(11):e038608.
    View in: PubMed
    Score: 0.014
  95. From Trials to Practice: Implementing a Clinical Intervention in Community Settings. J Prim Care Community Health. 2025 Jan-Dec; 16:21501319251339190.
    View in: PubMed
    Score: 0.014
  96. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 03; 393(1):51-61.
    View in: PubMed
    Score: 0.014
  97. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis. 2005 Dec; 183(2):301-7.
    View in: PubMed
    Score: 0.014
  98. Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial. J Am Coll Cardiol. 2025 Apr 01; 85(12):1317-1331.
    View in: PubMed
    Score: 0.014
  99. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 2005 Mar; 149(3):464-73.
    View in: PubMed
    Score: 0.014
  100. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025 Mar 04; 14(5):e038656.
    View in: PubMed
    Score: 0.014
  101. Early-onset atherosclerotic cardiovascular disease. Eur J Prev Cardiol. 2025 Jan 27; 32(2):100-112.
    View in: PubMed
    Score: 0.014
  102. Mid-life anti-inflammatory metabolites are inversely associated with long-term cardiovascular disease events. EBioMedicine. 2025 Feb; 112:105551.
    View in: PubMed
    Score: 0.014
  103. Trends in Cardiovascular Disease-Related Mortality in Texas. Tex Heart Inst J. 2024 Jul-Dec; 51(2):e248426.
    View in: PubMed
    Score: 0.014
  104. Inadequate Intensification of LDL-cholesterol lowering therapy after coronary revascularization: Insights from the GOULD registry. Int J Cardiol. 2025 Feb 15; 421:132916.
    View in: PubMed
    Score: 0.014
  105. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol. 2004 Nov 15; 94(10):1249-54.
    View in: PubMed
    Score: 0.014
  106. Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial. Clin Ther. 2004 Nov; 26(11):1855-64.
    View in: PubMed
    Score: 0.014
  107. Sociodemographic, lifestyle, and medical factors associated with calculated free testosterone concentrations in men: individual participant data meta-analyses. Eur J Endocrinol. 2024 Oct 29; 191(5):523-534.
    View in: PubMed
    Score: 0.014
  108. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol. 2004 Sep 15; 94(6):795-7.
    View in: PubMed
    Score: 0.014
  109. Long-term longitudinal analysis of 4,187 participants reveals insights into determinants of clonal hematopoiesis. Nat Commun. 2024 09 09; 15(1):7858.
    View in: PubMed
    Score: 0.014
  110. Predictors of incident stroke among individuals without coronary artery calcification: A pooled cohort analysis from the Multi-Ethnic Study of Atherosclerosis, Jackson Heart Study, and Framingham Heart Study. Vasc Med. 2024 12; 29(6):632-639.
    View in: PubMed
    Score: 0.014
  111. Comparing Cardiovascular Risk Classification of U.S. Adults According to Pooled Cohort Equations and PREVENT Equations: Cross-Sectional Analysis of the National Health and Nutrition Examination Survey. Ann Intern Med. 2024 Oct; 177(10):1444-1448.
    View in: PubMed
    Score: 0.014
  112. Lipoprotein(a) and Progression of Coronary Artery Calcification in a Pooled?U.S. Cohort. JACC Cardiovasc Imaging. 2024 Oct; 17(10):1265-1267.
    View in: PubMed
    Score: 0.014
  113. Associations of Ambulatory Blood Pressure Measurements With High-Sensitivity Troponin and Natriuretic Peptide Levels in SPRINT. Am J Hypertens. 2024 07 15; 37(8):571-579.
    View in: PubMed
    Score: 0.013
  114. Racial Differences in the Burden of Atherosclerotic Cardiovascular Disease Related to Elevated Lipoprotein(a) Levels: The ARIC Study. Circulation. 2024 Jul 16; 150(3):250-252.
    View in: PubMed
    Score: 0.013
  115. High-Sensitivity Troponin T, NT-proBNP, and Cognitive Outcomes in SPRINT. Hypertension. 2024 Sep; 81(9):1956-1965.
    View in: PubMed
    Score: 0.013
  116. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract. 2004 Jul; 58(7):653-8.
    View in: PubMed
    Score: 0.013
  117. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004 Jun 15; 93(12):1487-94.
    View in: PubMed
    Score: 0.013
  118. Associations of mid-to-late-life inflammation with late-life mobility and the influences of chronic comorbidities, race, and social determinants of health: The Atherosclerosis Risk in Communities Study. J Am Geriatr Soc. 2024 Aug; 72(8):2434-2445.
    View in: PubMed
    Score: 0.013
  119. Prognostic Value of Cardiovascular Biomarkers in the Population. JAMA. 2024 06 11; 331(22):1898-1909.
    View in: PubMed
    Score: 0.013
  120. Individual and Joint Associations of High-Sensitivity Troponin I and High-Sensitivity Troponin T with Cardiac Phenotypes and Outcomes in the General Population: An Analysis From the Dallas Heart Study. J Am Heart Assoc. 2024 Jul 02; 13(13):e034549.
    View in: PubMed
    Score: 0.013
  121. Clonal hematopoiesis driven by mutated DNMT3A promotes inflammatory bone loss. Cell. 2024 Jul 11; 187(14):3690-3711.e19.
    View in: PubMed
    Score: 0.013
  122. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab. 2004 Jun; 89(6):2697-703.
    View in: PubMed
    Score: 0.013
  123. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024 09 12; 391(10):913-925.
    View in: PubMed
    Score: 0.013
  124. Association of High-Density Lipoprotein Parameters and Risk of Heart?Failure: A Multicohort Analysis. JACC Heart Fail. 2024 Jul; 12(7):1242-1253.
    View in: PubMed
    Score: 0.013
  125. Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men : Individual Participant Data Meta-analyses. Ann Intern Med. 2024 06; 177(6):768-781.
    View in: PubMed
    Score: 0.013
  126. Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
    View in: PubMed
    Score: 0.013
  127. A Technology-Assisted Web Application for Consumer Access to a Nonprescription Statin Medication. J Am Coll Cardiol. 2024 May 28; 83(21):2080-2088.
    View in: PubMed
    Score: 0.013
  128. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. N Engl J Med. 2024 05 16; 390(19):1781-1792.
    View in: PubMed
    Score: 0.013
  129. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. J Am Coll Cardiol. 2024 Apr 23; 83(16):1529-1539.
    View in: PubMed
    Score: 0.013
  130. Galectin-3, Metabolic Risk, and Incident Heart Failure: The ARIC Study. J Am Heart Assoc. 2024 Mar 19; 13(6):e031607.
    View in: PubMed
    Score: 0.013
  131. Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol. JAMA Cardiol. 2024 Mar 01; 9(3):263-271.
    View in: PubMed
    Score: 0.013
  132. Racial and ethnic disparities in cardiovascular disease - analysis across major US national databases. J Natl Med Assoc. 2024 Jun; 116(3):258-270.
    View in: PubMed
    Score: 0.013
  133. Large-Scale Proteomics Identifies Novel Biomarkers and Circulating Risk Factors for Aortic Stenosis. J Am Coll Cardiol. 2024 02 06; 83(5):577-591.
    View in: PubMed
    Score: 0.013
  134. Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction. JAMA Netw Open. 2024 01 02; 7(1):e2353244.
    View in: PubMed
    Score: 0.013
  135. Fluvastatin reduces cardiac mortality in patients with coronary heart disease. Cardiovasc Drugs Ther. 2004 Jan; 18(1):67-75.
    View in: PubMed
    Score: 0.013
  136. Novel Size-Based High-Density Lipoprotein Subspecies and Incident Vascular Events. J Am Heart Assoc. 2023 11 07; 12(21):e031160.
    View in: PubMed
    Score: 0.013
  137. Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J. 2003 Nov; 146(5):862-9.
    View in: PubMed
    Score: 0.013
  138. Factors Associated With Circulating Sex Hormones in Men : Individual Participant Data Meta-analyses. Ann Intern Med. 2023 09; 176(9):1221-1234.
    View in: PubMed
    Score: 0.013
  139. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N Engl J Med. 2023 10 05; 389(14):1273-1285.
    View in: PubMed
    Score: 0.013
  140. Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life. Sci Transl Med. 2023 07 19; 15(705):eadf5681.
    View in: PubMed
    Score: 0.013
  141. Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. Am J Cardiol. 2003 May 01; 91(9):1134-6.
    View in: PubMed
    Score: 0.012
  142. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003 May 20; 107(19):2409-15.
    View in: PubMed
    Score: 0.012
  143. Growth Differentiation Factor 15 and Risk of Bleeding Events: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2023 03 21; 12(6):e023847.
    View in: PubMed
    Score: 0.012
  144. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol. 2003 Mar 06; 91(5A):25C-27C; discussion 28C.
    View in: PubMed
    Score: 0.012
  145. Association of Long-term Change in N-Terminal Pro-B-Type Natriuretic Peptide With Incident Heart Failure and Death. JAMA Cardiol. 2023 03 01; 8(3):222-230.
    View in: PubMed
    Score: 0.012
  146. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab. 2002 Nov; 4(6):407-14.
    View in: PubMed
    Score: 0.012
  147. Diabetes Duration and Subclinical Myocardial Injury: The Atherosclerosis Risk in Communities Study (ARIC). Clin Chem. 2022 10 06; 68(10):1272-1280.
    View in: PubMed
    Score: 0.012
  148. Statin Use and Risk of Diabetes by Subclinical Atherosclerosis Burden (from a Multi-Ethnic Study of Atherosclerosis Report). Am J Cardiol. 2022 12 01; 184:7-13.
    View in: PubMed
    Score: 0.012
  149. Long-term changes in plasma proteomic profiles in premenopausal and postmenopausal Black and White women: the Atherosclerosis Risk in Communities study. Menopause. 2022 10 01; 29(10):1150-1160.
    View in: PubMed
    Score: 0.012
  150. Association of polygenic risk scores with incident atherosclerotic cardiovascular disease events among individuals with coronary artery calcium score of zero: The multi-ethnic study of atherosclerosis. Prog Cardiovasc Dis. 2022 Sep-Oct; 74:19-27.
    View in: PubMed
    Score: 0.012
  151. Growth Differentiation Factor 15 and the Subsequent Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities Study. Clin Chem. 2022 07 27; 68(8):1084-1093.
    View in: PubMed
    Score: 0.012
  152. Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2022 06 07; 11(11):e024870.
    View in: PubMed
    Score: 0.012
  153. Obesity, Galectin-3, and Incident Heart Failure: The ARIC Study. J Am Heart Assoc. 2022 05 03; 11(9):e023238.
    View in: PubMed
    Score: 0.012
  154. Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT. J Am Heart Assoc. 2022 04 05; 11(7):e024999.
    View in: PubMed
    Score: 0.012
  155. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. Eur J Prev Cardiol. 2022 03 11; 29(2):e53-e64.
    View in: PubMed
    Score: 0.011
  156. Diabetes, GDF-15 and incident heart failure: the atherosclerosis risk in communities study. Diabetologia. 2022 06; 65(6):955-963.
    View in: PubMed
    Score: 0.011
  157. A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study. J Am Heart Assoc. 2022 03 15; 11(6):e024176.
    View in: PubMed
    Score: 0.011
  158. Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Netw Open. 2022 02 01; 5(2):e2148172.
    View in: PubMed
    Score: 0.011
  159. NT-pro B-type natriuretic peptide, early menopause, and incident heart failure in postmenopausal women of the ARIC study. Menopause. 2022 01 14; 29(3):309-316.
    View in: PubMed
    Score: 0.011
  160. Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. Sci Rep. 2022 01 12; 12(1):577.
    View in: PubMed
    Score: 0.011
  161. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001 Dec 18; 104(25):3046-51.
    View in: PubMed
    Score: 0.011
  162. Proteomics and Risk of Atrial Fibrillation in Older Adults (From the Atherosclerosis Risk in Communities [ARIC] Study). Am J Cardiol. 2021 12 15; 161:42-50.
    View in: PubMed
    Score: 0.011
  163. Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis. Circulation. 2022 01 25; 145(4):259-267.
    View in: PubMed
    Score: 0.011
  164. Polygenic Risk Scores for Kidney Function and Their Associations with Circulating Proteome, and Incident Kidney Diseases. J Am Soc Nephrol. 2021 12 01; 32(12):3161-3173.
    View in: PubMed
    Score: 0.011
  165. The Fifth-Generation Cardiac Troponin T and Cardiovascular Disease in the Community. J Am Coll Cardiol. 2021 11 16; 78(20):2019-2021.
    View in: PubMed
    Score: 0.011
  166. Clonal Hematopoiesis Is Associated With Higher Risk of Stroke. Stroke. 2022 03; 53(3):788-797.
    View in: PubMed
    Score: 0.011
  167. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J. 2021 11 07; 42(42):4324-4332.
    View in: PubMed
    Score: 0.011
  168. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Circulation. 2021 11 30; 144(22):1750-1759.
    View in: PubMed
    Score: 0.011
  169. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation. 2021 12 07; 144(23):1845-1855.
    View in: PubMed
    Score: 0.011
  170. Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. J Clin Lipidol. 2021 Nov-Dec; 15(6):832-839.
    View in: PubMed
    Score: 0.011
  171. Technology-Assisted Self-Selection of Candidates for Nonprescription Statin?Therapy. J Am Coll Cardiol. 2021 09 14; 78(11):1114-1123.
    View in: PubMed
    Score: 0.011
  172. Proteins Associated with Risk of Kidney Function Decline in the General Population. J Am Soc Nephrol. 2021 09; 32(9):2291-2302.
    View in: PubMed
    Score: 0.011
  173. Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network. Circ Cardiovasc Qual Outcomes. 2021 09; 14(9):e007485.
    View in: PubMed
    Score: 0.011
  174. Association of Longitudinal Changes in Cardiac Biomarkers With Atrial and Ventricular Arrhythmias (from the Atherosclerosis Risk in Communities [ARIC] Study). Am J Cardiol. 2021 11 01; 158:45-52.
    View in: PubMed
    Score: 0.011
  175. What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. J Am Heart Assoc. 2021 08 17; 10(16):e020893.
    View in: PubMed
    Score: 0.011
  176. Duration of Diabetes and Incident?Heart?Failure: The ARIC (Atherosclerosis Risk In Communities) Study. JACC Heart Fail. 2021 08; 9(8):594-603.
    View in: PubMed
    Score: 0.011
  177. Supplemental Association of Clonal Hematopoiesis With Incident Heart?Failure. J Am Coll Cardiol. 2021 07 06; 78(1):42-52.
    View in: PubMed
    Score: 0.011
  178. Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2021 07 01; 6(7):782-790.
    View in: PubMed
    Score: 0.011
  179. High Burden of Subclinical and Cardiovascular Disease Risk in Adults With Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2021 07; 44(7):1657-1663.
    View in: PubMed
    Score: 0.011
  180. Outcomes of Acute Myocardial Infarction in Patients with Familial Hypercholesteremia. Am J Med. 2021 08; 134(8):992-1001.e4.
    View in: PubMed
    Score: 0.011
  181. Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. Circulation. 2021 06 15; 143(24):2370-2383.
    View in: PubMed
    Score: 0.011
  182. Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices. Nat Commun. 2021 04 12; 12(1):2182.
    View in: PubMed
    Score: 0.011
  183. Premature Atherosclerotic Cardiovascular Disease Risk Among Patients with Inflammatory Bowel Disease. Am J Med. 2021 08; 134(8):1047-1051.e2.
    View in: PubMed
    Score: 0.011
  184. Recreational substance use among patients with premature atherosclerotic cardiovascular disease. Heart. 2021 04; 107(8):650-656.
    View in: PubMed
    Score: 0.011
  185. Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The ARIC Study. J Am Coll Cardiol. 2021 02 09; 77(5):559-571.
    View in: PubMed
    Score: 0.011
  186. Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2021 05 01; 146:15-21.
    View in: PubMed
    Score: 0.011
  187. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther. 2001 Feb; 23(2):177-92.
    View in: PubMed
    Score: 0.011
  188. High-Sensitivity Cardiac Troponin, Natriuretic Peptide, and Long-Term Risk of Acute Kidney Injury: The Atherosclerosis Risk in Communities (ARIC) Study. Clin Chem. 2021 01 08; 67(1):298-307.
    View in: PubMed
    Score: 0.011
  189. Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7. Cardiovasc Drugs Ther. 2022 02; 36(1):93-102.
    View in: PubMed
    Score: 0.011
  190. Associations Between Carotid Artery Plaque Burden, Plaque Characteristics, and Cardiovascular Events: The ARIC Carotid Magnetic Resonance Imaging Study. JAMA Cardiol. 2021 01 01; 6(1):79-86.
    View in: PubMed
    Score: 0.011
  191. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020 12 08; 324(22):2268-2280.
    View in: PubMed
    Score: 0.010
  192. Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-Associated Side Effects. J Am Heart Assoc. 2020 11 17; 9(22):e017915.
    View in: PubMed
    Score: 0.010
  193. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses. Circulation. 2021 01 05; 143(1):33-44.
    View in: PubMed
    Score: 0.010
  194. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol. 2000 Nov 01; 36(5):1572-8.
    View in: PubMed
    Score: 0.010
  195. Molecular Signature of Multisystem Cardiometabolic Stress and Its Association With Prognosis. JAMA Cardiol. 2020 10 01; 5(10):1144-1153.
    View in: PubMed
    Score: 0.010
  196. Sex Hormones and Incident Heart Failure in Men and Postmenopausal Women: The Atherosclerosis Risk in Communities Study. J Clin Endocrinol Metab. 2020 10 01; 105(10).
    View in: PubMed
    Score: 0.010
  197. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. Am J Cardiol. 2000 Oct 01; 86(7):759-63.
    View in: PubMed
    Score: 0.010
  198. Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovasc Drugs Ther. 2021 06; 35(3):533-538.
    View in: PubMed
    Score: 0.010
  199. Statin Prescription Rates, Adherence, and Associated Clinical Outcomes Among Women with PAD and ICVD. Cardiovasc Drugs Ther. 2020 12; 34(6):745-754.
    View in: PubMed
    Score: 0.010
  200. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. J Am Coll Cardiol. 2020 08 18; 76(7):781-793.
    View in: PubMed
    Score: 0.010
  201. High-Sensitivity Cardiac Troponin I and T for Cardiovascular Risk Stratification in Adults With Diabetes. Diabetes Care. 2020 10; 43(10):e144-e146.
    View in: PubMed
    Score: 0.010
  202. Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Netw Open. 2020 08 03; 3(8):e2011051.
    View in: PubMed
    Score: 0.010
  203. Combining Biomarkers and Imaging for Short-Term Assessment of Cardiovascular Disease Risk in Apparently Healthy Adults. J Am Heart Assoc. 2020 08 04; 9(15):e015410.
    View in: PubMed
    Score: 0.010
  204. Fibrosis and Inflammatory Markers and Long-Term Risk of Peripheral Artery Disease: The ARIC Study. Arterioscler Thromb Vasc Biol. 2020 09; 40(9):2322-2331.
    View in: PubMed
    Score: 0.010
  205. Autoimmune Rheumatic Diseases and Premature Atherosclerotic Cardiovascular Disease: An Analysis From the VITAL Registry. Am J Med. 2020 12; 133(12):1424-1432.e1.
    View in: PubMed
    Score: 0.010
  206. Associations Between High-Density Lipoprotein Particles and Ischemic Events by Vascular Domain, Sex, and Ethnicity: A Pooled Cohort Analysis. Circulation. 2020 08 18; 142(7):657-669.
    View in: PubMed
    Score: 0.010
  207. Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. Curr Atheroscler Rep. 2020 06 03; 22(7):25.
    View in: PubMed
    Score: 0.010
  208. Age-Stratified Sex Disparities in Care and Outcomes in Patients With ST-Elevation Myocardial Infarction. Am J Med. 2020 11; 133(11):1293-1301.e1.
    View in: PubMed
    Score: 0.010
  209. Physical Activity and Incident Heart Failure in High-Risk Subgroups: The ARIC Study. J Am Heart Assoc. 2020 05 18; 9(10):e014885.
    View in: PubMed
    Score: 0.010
  210. Temporal Trends in E-Cigarette Use Among U.S. Adults: Behavioral Risk Factor Surveillance System, 2016 to 2018. Am J Med. 2020 09; 133(9):e508-e511.
    View in: PubMed
    Score: 0.010
  211. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes Care. 2020 05; 43(5):1077-1084.
    View in: PubMed
    Score: 0.010
  212. Cardiac Biomarkers and Subsequent Risk of Hospitalization With Bleeding in the Community: Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2020 03 03; 9(5):e013560.
    View in: PubMed
    Score: 0.010
  213. Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes. JAMA. 2020 Jan 28; 323(4):329-338.
    View in: PubMed
    Score: 0.010
  214. Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study. Circulation. 2020 03 24; 141(12):957-967.
    View in: PubMed
    Score: 0.010
  215. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol. 2000 Jan; 35(1):89-95.
    View in: PubMed
    Score: 0.010
  216. Associations of High-Sensitivity Cardiac Troponin and Natriuretic Peptide With Subsequent Risk of Infection in Persons Without Cardiovascular Disease: The Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2019 12 31; 188(12):2146-2155.
    View in: PubMed
    Score: 0.010
  217. Relationship of extracellular volume assessed on cardiac magnetic resonance and serum cardiac troponins and natriuretic peptides with heart failure outcomes. Sci Rep. 2019 12 27; 9(1):20168.
    View in: PubMed
    Score: 0.010
  218. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
    View in: PubMed
    Score: 0.010
  219. Myocardial Extracellular Volume Fraction Adds Prognostic Information Beyond Myocardial Replacement Fibrosis. Circ Cardiovasc Imaging. 2019 12; 12(12):e009535.
    View in: PubMed
    Score: 0.010
  220. Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. Am Heart J. 2020 03; 221:60-66.
    View in: PubMed
    Score: 0.010
  221. Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration. Nat Commun. 2019 Nov 12; 10(1):5121.
    View in: PubMed
    Score: 0.010
  222. Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. Circulation. 2019 12 17; 140(25):2076-2088.
    View in: PubMed
    Score: 0.010
  223. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. Circulation. 2020 02 04; 141(5):367-375.
    View in: PubMed
    Score: 0.010
  224. Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. JAMA Cardiol. 2019 10 01; 4(10):997-1006.
    View in: PubMed
    Score: 0.010
  225. Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17?180 Individuals. Circ Res. 2019 09 27; 125(8):773-782.
    View in: PubMed
    Score: 0.010
  226. High-Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change. J Am Geriatr Soc. 2019 11; 67(11):2353-2361.
    View in: PubMed
    Score: 0.010
  227. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. Postgrad Med. 2019 Aug; 131(6):390-396.
    View in: PubMed
    Score: 0.010
  228. Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction. Am Heart J. 2019 10; 216:62-73.
    View in: PubMed
    Score: 0.010
  229. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study). Am J Cardiol. 2019 09 01; 124(5):696-701.
    View in: PubMed
    Score: 0.009
  230. Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. Am J Epidemiol. 2019 Jun 01; 188(6):1033-1054.
    View in: PubMed
    Score: 0.009
  231. Metabolomic Pattern Predicts Incident Coronary Heart Disease. Arterioscler Thromb Vasc Biol. 2019 07; 39(7):1475-1482.
    View in: PubMed
    Score: 0.009
  232. ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change. Neurology. 2019 05 28; 92(22):e2580-e2593.
    View in: PubMed
    Score: 0.009
  233. Relation of Isolated Systolic Hypertension and Pulse Pressure to High-Sensitivity Cardiac Troponin-T and N-Terminal pro-B-Type Natriuretic Peptide in Older Adults (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2019 07 15; 124(2):245-252.
    View in: PubMed
    Score: 0.009
  234. Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. Nat Genet. 2019 Apr; 51(4):636-648.
    View in: PubMed
    Score: 0.009
  235. Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circ Genom Precis Med. 2019 04; 12(4):e002470.
    View in: PubMed
    Score: 0.009
  236. Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circ Genom Precis Med. 2019 04; 12(4):e002471.
    View in: PubMed
    Score: 0.009
  237. Effects of Icosapent Ethyl on Total?Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019 06 11; 73(22):2791-2802.
    View in: PubMed
    Score: 0.009
  238. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019 03 14; 380(11):1022-1032.
    View in: PubMed
    Score: 0.009
  239. Central and peripheral pulse wave velocity and subclinical myocardial stress and damage in older adults. PLoS One. 2019; 14(2):e0212892.
    View in: PubMed
    Score: 0.009
  240. Sleep apnea and galectin-3: possible sex-specific relationship. Sleep Breath. 2019 Dec; 23(4):1107-1114.
    View in: PubMed
    Score: 0.009
  241. Reproducibility and Variability of Protein Analytes Measured Using a Multiplexed Modified Aptamer Assay. J Appl Lab Med. 2019 07; 4(1):30-39.
    View in: PubMed
    Score: 0.009
  242. Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans: The Jackson Heart Study. JAMA Cardiol. 2019 01 01; 4(1):51-58.
    View in: PubMed
    Score: 0.009
  243. Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004817.
    View in: PubMed
    Score: 0.009
  244. Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study. Atherosclerosis. 2019 03; 282:52-56.
    View in: PubMed
    Score: 0.009
  245. Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD. Clin J Am Soc Nephrol. 2018 12 07; 13(12):1842-1850.
    View in: PubMed
    Score: 0.009
  246. Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. Am J Hum Genet. 2018 11 01; 103(5):691-706.
    View in: PubMed
    Score: 0.009
  247. Effect of Evolocumab on Coronary?Plaque Composition. J Am Coll Cardiol. 2018 10 23; 72(17):2012-2021.
    View in: PubMed
    Score: 0.009
  248. Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study. Thromb Haemost. 2018 Nov; 118(11):1940-1950.
    View in: PubMed
    Score: 0.009
  249. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018 10 07; 39(38):3499-3507.
    View in: PubMed
    Score: 0.009
  250. Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial. JAMA Cardiol. 2018 09 01; 3(9):806-814.
    View in: PubMed
    Score: 0.009
  251. Diagnostic Performance of 1,5-Anhydroglucitol Compared to 2-H Glucose in the Atherosclerosis Risk in Communities Study. Clin Chem. 2018 10; 64(10):1536-1537.
    View in: PubMed
    Score: 0.009
  252. Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. J Am Coll Cardiol. 2018 07 10; 72(2):156-169.
    View in: PubMed
    Score: 0.009
  253. High-sensitivity cardiac troponin and natriuretic peptide with risk of lower-extremity peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) Study. Eur Heart J. 2018 07 01; 39(25):2412-2419.
    View in: PubMed
    Score: 0.009
  254. Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease. JAAPA. 2018 Jul; 31(7):39-45.
    View in: PubMed
    Score: 0.009
  255. Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. J Am Heart Assoc. 2018 06 09; 7(12).
    View in: PubMed
    Score: 0.009
  256. Orthostatic Hypotension and Risk of Clinical and Subclinical Cardiovascular Disease in Middle-Aged Adults. J Am Heart Assoc. 2018 05 07; 7(10).
    View in: PubMed
    Score: 0.009
  257. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol. 1998 May; 18(5):723-31.
    View in: PubMed
    Score: 0.009
  258. Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2018 07; 274:86-93.
    View in: PubMed
    Score: 0.009
  259. The association of mid-to late-life systemic inflammation with white matter structure in older adults: The Atherosclerosis Risk in Communities Study. Neurobiol Aging. 2018 08; 68:26-33.
    View in: PubMed
    Score: 0.009
  260. Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vasc Med. 2018 06; 23(3):232-240.
    View in: PubMed
    Score: 0.009
  261. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis. J Womens Health (Larchmt). 2018 09; 27(9):1170-1176.
    View in: PubMed
    Score: 0.009
  262. Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study. JAMA Cardiol. 2018 03 01; 3(3):200-206.
    View in: PubMed
    Score: 0.009
  263. Usefulness of Lipoprotein-Associated Phospholipase A2 Activity and C-Reactive Protein in Identifying High-Risk Smokers for Atherosclerotic Cardiovascular Disease (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2018 05 01; 121(9):1056-1064.
    View in: PubMed
    Score: 0.009
  264. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
    View in: PubMed
    Score: 0.009
  265. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiol. 2018 02 01; 3(2):164-168.
    View in: PubMed
    Score: 0.009
  266. Six-Year Changes in Physical Activity and the Risk of Incident Heart Failure: ARIC Study. Circulation. 2018 05 15; 137(20):2142-2151.
    View in: PubMed
    Score: 0.009
  267. Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. J Am Heart Assoc. 2017 Dec 15; 6(12).
    View in: PubMed
    Score: 0.009
  268. SES, Heart Failure, and N-terminal Pro-b-type Natriuretic Peptide: The Atherosclerosis Risk in Communities Study. Am J Prev Med. 2018 02; 54(2):229-236.
    View in: PubMed
    Score: 0.009
  269. Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts. Am Heart J. 2018 03; 197:62-69.
    View in: PubMed
    Score: 0.009
  270. Lipoprotein(a) and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study. Atherosclerosis. 2018 01; 268:63-67.
    View in: PubMed
    Score: 0.009
  271. Relation of Lifestyle Factors and Life's Simple 7 Score to Temporal Reduction in Troponin Levels Measured by a High-Sensitivity Assay (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2018 02 15; 121(4):430-436.
    View in: PubMed
    Score: 0.009
  272. Weight History and Subclinical Myocardial Damage. Clin Chem. 2018 01; 64(1):201-209.
    View in: PubMed
    Score: 0.008
  273. Midlife systemic inflammatory markers are associated with late-life brain volume: The ARIC study. Neurology. 2017 Nov 28; 89(22):2262-2270.
    View in: PubMed
    Score: 0.008
  274. Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care. Popul Health Manag. 2018 06; 21(3):209-216.
    View in: PubMed
    Score: 0.008
  275. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH? patient registry. Atherosclerosis. 2017 Dec; 267:19-26.
    View in: PubMed
    Score: 0.008
  276. Association of midlife lipids with 20-year cognitive change: A cohort study. Alzheimers Dement. 2018 02; 14(2):167-177.
    View in: PubMed
    Score: 0.008
  277. Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. Kidney Int. 2018 01; 93(1):252-259.
    View in: PubMed
    Score: 0.008
  278. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 09 21; 377(12):1119-1131.
    View in: PubMed
    Score: 0.008
  279. Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. J Am Heart Assoc. 2017 Aug 03; 6(8).
    View in: PubMed
    Score: 0.008
  280. Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2017 Oct; 192:19-25.
    View in: PubMed
    Score: 0.008
  281. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. Atherosclerosis. 2017 Aug; 263:137-144.
    View in: PubMed
    Score: 0.008
  282. Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative. Clin Rheumatol. 2017 Sep; 36(9):2121-2128.
    View in: PubMed
    Score: 0.008
  283. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes Endocrinol. 2017 07; 5(7):534-543.
    View in: PubMed
    Score: 0.008
  284. Physical Activity, Obesity, and Subclinical?Myocardial Damage. JACC Heart Fail. 2017 05; 5(5):377-384.
    View in: PubMed
    Score: 0.008
  285. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis. 2017 06; 261:12-18.
    View in: PubMed
    Score: 0.008
  286. Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts. Circulation. 2017 05 30; 135(22):2119-2132.
    View in: PubMed
    Score: 0.008
  287. An NPPB Promoter Polymorphism Associated With Elevated N-Terminal pro-B-Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality. J Am Heart Assoc. 2017 Mar 24; 6(4).
    View in: PubMed
    Score: 0.008
  288. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol. 2017 Mar; 40(3):138-148.
    View in: PubMed
    Score: 0.008
  289. Serum vitamin D and change in lipid levels over 5?y: The Atherosclerosis Risk in Communities study. Nutrition. 2017 Jun; 38:85-93.
    View in: PubMed
    Score: 0.008
  290. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. Int J Cardiol. 2017 Apr 15; 233:61-66.
    View in: PubMed
    Score: 0.008
  291. Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. J Am Heart Assoc. 2017 01 10; 6(1).
    View in: PubMed
    Score: 0.008
  292. Myocardial Injury, Obesity, and the Obesity Paradox: The ARIC Study. JACC Heart Fail. 2017 01; 5(1):56-63.
    View in: PubMed
    Score: 0.008
  293. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016 12 13; 316(22):2373-2384.
    View in: PubMed
    Score: 0.008
  294. Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. J Am Coll Cardiol. 2016 12 06; 68(22):2488-2490.
    View in: PubMed
    Score: 0.008
  295. High-Sensitivity Cardiac Troponin T (hs-cTnT) as a Predictor of Incident Diabetes in the Atherosclerosis Risk in Communities Study. Diabetes Care. 2017 Feb; 40(2):261-269.
    View in: PubMed
    Score: 0.008
  296. Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials). Am J Cardiol. 2017 Feb 01; 119(3):397-403.
    View in: PubMed
    Score: 0.008
  297. Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes Obes Metab. 2017 01; 19(1):98-107.
    View in: PubMed
    Score: 0.008
  298. On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J. 2016 Dec; 182:89-96.
    View in: PubMed
    Score: 0.008
  299. Practice-Level Variation in?Statin Use Among Patients With Diabetes: Insights From the PINNACLE Registry. J Am Coll Cardiol. 2016 09 20; 68(12):1368-9.
    View in: PubMed
    Score: 0.008
  300. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes Endocrinol. 2016 10; 4(10):840-9.
    View in: PubMed
    Score: 0.008
  301. Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events: Implications for Blood Pressure Control. J Am Coll Cardiol. 2016 10 18; 68(16):1713-1722.
    View in: PubMed
    Score: 0.008
  302. Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act. Am Heart J. 2016 Nov; 181:74-82.
    View in: PubMed
    Score: 0.008
  303. Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. Atherosclerosis. 2016 10; 253:156-163.
    View in: PubMed
    Score: 0.008
  304. Magnetic Resonance Venous Volume Measurements in Peripheral Artery Disease (from ELIMIT). Am J Cardiol. 2016 Nov 01; 118(9):1399-1404.
    View in: PubMed
    Score: 0.008
  305. US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. J Clin Lipidol. 2016 Sep-Oct; 10(5):1223-9.
    View in: PubMed
    Score: 0.008
  306. Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death. JAMA Cardiol. 2016 08 01; 1(5):519-28.
    View in: PubMed
    Score: 0.008
  307. Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. Am J Cardiol. 2016 Oct 15; 118(8):1144-1149.
    View in: PubMed
    Score: 0.008
  308. Obesity and Subtypes of Incident Cardiovascular Disease. J Am Heart Assoc. 2016 07 28; 5(8).
    View in: PubMed
    Score: 0.008
  309. Alcohol Consumption and Cardiac Biomarkers: The Atherosclerosis Risk in Communities (ARIC) Study. Clin Chem. 2016 09; 62(9):1202-10.
    View in: PubMed
    Score: 0.008
  310. Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat. 2016 09; 125:57-64.
    View in: PubMed
    Score: 0.008
  311. Accuracy of the Atherosclerotic Cardiovascular Risk Equation in?a?Large?Contemporary, Multiethnic?Population. J Am Coll Cardiol. 2016 05 10; 67(18):2118-2130.
    View in: PubMed
    Score: 0.008
  312. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016 Apr 19; 315(15):1580-90.
    View in: PubMed
    Score: 0.008
  313. Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database. Clin Cardiol. 2016 Apr; 39(4):185-91.
    View in: PubMed
    Score: 0.008
  314. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation. 1996 Apr 01; 93(7):1334-8.
    View in: PubMed
    Score: 0.008
  315. Influence of cigarette smoking on cardiac biomarkers: the Atherosclerosis Risk in Communities (ARIC) Study. Eur J Heart Fail. 2016 06; 18(6):629-37.
    View in: PubMed
    Score: 0.008
  316. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Circ Cardiovasc Genet. 2016 Jun; 9(3):240-9.
    View in: PubMed
    Score: 0.008
  317. Determinants of minimal elevation in high-sensitivity cardiac troponin T in the general population. Clin Biochem. 2016 Jun; 49(9):657-662.
    View in: PubMed
    Score: 0.008
  318. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). Am Heart J. 2016 Jun; 176:83-92.
    View in: PubMed
    Score: 0.008
  319. The impact of multiple single day blood pressure readings on cardiovascular risk estimation: The Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2016 09; 23(14):1529-36.
    View in: PubMed
    Score: 0.008
  320. The Association of Socioeconomic Status With Subclinical Myocardial Damage, Incident Cardiovascular Events, and Mortality in the ARIC Study. Am J Epidemiol. 2016 Mar 01; 183(5):452-61.
    View in: PubMed
    Score: 0.008
  321. Causal Role of Alcohol Consumption in an Improved Lipid Profile: The Atherosclerosis Risk in Communities (ARIC) Study. PLoS One. 2016; 11(2):e0148765.
    View in: PubMed
    Score: 0.008
  322. Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. Am J Cardiovasc Drugs. 2016 Feb; 16(1):55-65.
    View in: PubMed
    Score: 0.007
  323. N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2016 Feb 16; 133(7):631-8.
    View in: PubMed
    Score: 0.007
  324. Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2016 May; 39(5):677-85.
    View in: PubMed
    Score: 0.007
  325. Increased expression of ICAM-1 in a case of accelerated coronary artery disease after heart transplantation. Tex Heart Inst J. 1996; 23(4):293-5.
    View in: PubMed
    Score: 0.007
  326. Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD. Circ Cardiovasc Genet. 2016 Feb; 9(1):71-8.
    View in: PubMed
    Score: 0.007
  327. Prognostic Significance of High-Sensitivity Cardiac Troponin T Concentrations between the Limit of Blank and Limit of Detection in Community-Dwelling Adults: A Metaanalysis. Clin Chem. 2015 Dec; 61(12):1524-31.
    View in: PubMed
    Score: 0.007
  328. Severity of hypoxia modulates effect of CPAP on myocardial stress as measured by highly sensitive troponin T. Respir Res. 2015 Oct 16; 16:126.
    View in: PubMed
    Score: 0.007
  329. Ideal Cardiovascular Health During Adult Life and Cardiovascular Structure and Function Among the Elderly. Circulation. 2015 Nov 24; 132(21):1979-89.
    View in: PubMed
    Score: 0.007
  330. Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. Lipids Health Dis. 2015 Sep 04; 14:103.
    View in: PubMed
    Score: 0.007
  331. Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort: The Atherosclerosis Risk in Communities-Sleep Heart Health Study. Circulation. 2015 Oct 06; 132(14):1329-37.
    View in: PubMed
    Score: 0.007
  332. Validity of self-report of lipid medication use: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2015 Oct; 242(2):625-9.
    View in: PubMed
    Score: 0.007
  333. Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study. Am Heart J. 2015 Nov; 170(5):961-7.
    View in: PubMed
    Score: 0.007
  334. High-Sensitivity Cardiac Troponin T and Risk of Hypertension. Circulation. 2015 Sep 01; 132(9):825-33.
    View in: PubMed
    Score: 0.007
  335. Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study. Atherosclerosis. 2015 Aug; 241(2):641-8.
    View in: PubMed
    Score: 0.007
  336. Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015 Aug 18; 132(7):578-85.
    View in: PubMed
    Score: 0.007
  337. Racial differences in circulating natriuretic peptide levels: the atherosclerosis risk in communities study. J Am Heart Assoc. 2015 May 21; 4(5).
    View in: PubMed
    Score: 0.007
  338. Improving Adiponectin Levels in Individuals With Diabetes and Obesity: Insights From Look AHEAD. Diabetes Care. 2015 Aug; 38(8):1544-50.
    View in: PubMed
    Score: 0.007
  339. Recalibration of blood analytes over 25 years in the atherosclerosis risk in communities study: impact of recalibration on chronic kidney disease prevalence and incidence. Clin Chem. 2015 Jul; 61(7):938-47.
    View in: PubMed
    Score: 0.007
  340. Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. Am Heart J. 2015 Aug; 170(2):380-9.
    View in: PubMed
    Score: 0.007
  341. Patterns and determinants of temporal change in high-sensitivity cardiac troponin-T: The Atherosclerosis Risk in Communities Cohort Study. Int J Cardiol. 2015; 187:651-7.
    View in: PubMed
    Score: 0.007
  342. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial. Atherosclerosis. 2015 Jun; 240(2):490-6.
    View in: PubMed
    Score: 0.007
  343. N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) and Risk of Hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Hypertens. 2015 Oct; 28(10):1262-6.
    View in: PubMed
    Score: 0.007
  344. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1500-9.
    View in: PubMed
    Score: 0.007
  345. A common variant in the CLDN7/ELP5 locus predicts adiponectin change with lifestyle intervention and improved fitness in obese individuals with diabetes. Physiol Genomics. 2015 Jun; 47(6):215-24.
    View in: PubMed
    Score: 0.007
  346. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry. J Am Coll Cardiol. 2015 Jan 20; 65(2):111-21.
    View in: PubMed
    Score: 0.007
  347. Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study. Mov Disord. 2015 Apr; 30(4):552-9.
    View in: PubMed
    Score: 0.007
  348. Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. J Am Coll Cardiol. 2014 Dec 30; 64(25):2743-9.
    View in: PubMed
    Score: 0.007
  349. The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. J Hepatol. 2015 Apr; 62(4):841-7.
    View in: PubMed
    Score: 0.007
  350. sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Diabetes Complications. 2015 Mar; 29(2):180-5.
    View in: PubMed
    Score: 0.007
  351. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014 Nov 27; 371(22):2072-82.
    View in: PubMed
    Score: 0.007
  352. FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. JACC Cardiovasc Imaging. 2015 Apr; 8(4):493-494.
    View in: PubMed
    Score: 0.007
  353. High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities study. Hypertension. 2015 Jan; 65(1):78-84.
    View in: PubMed
    Score: 0.007
  354. Association of high-sensitivity cardiac troponin T and natriuretic peptide with incident ESRD: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis. 2015 Apr; 65(4):550-8.
    View in: PubMed
    Score: 0.007
  355. Obesity, subclinical myocardial injury, and incident heart failure. JACC Heart Fail. 2014 Dec; 2(6):600-7.
    View in: PubMed
    Score: 0.007
  356. High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2015 Jan; 169(1):31-8.e3.
    View in: PubMed
    Score: 0.007
  357. The challenges of genome-wide interaction studies: lessons to learn from the analysis of HDL blood levels. PLoS One. 2014; 9(10):e109290.
    View in: PubMed
    Score: 0.007
  358. Development of chagas cardiac manifestations among Texas blood donors. Am J Cardiol. 2015 Jan 01; 115(1):113-7.
    View in: PubMed
    Score: 0.007
  359. Association of body mass index and waist circumference with subclinical atherosclerosis in retired NFL players. South Med J. 2014 Oct; 107(10):633-9.
    View in: PubMed
    Score: 0.007
  360. Relation between playing position and coronary artery calcium scores in retired National Football League players. Am J Cardiol. 2014 Dec 15; 114(12):1836-40.
    View in: PubMed
    Score: 0.007
  361. Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin. Arterioscler Thromb Vasc Biol. 2014 Nov; 34(11):2465-72.
    View in: PubMed
    Score: 0.007
  362. Low-density lipoprotein electronegativity is a novel cardiometabolic risk factor. PLoS One. 2014; 9(9):e107340.
    View in: PubMed
    Score: 0.007
  363. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care. 2014 Nov; 37(11):3114-20.
    View in: PubMed
    Score: 0.007
  364. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation. 2014 Oct 14; 130(16):1374-82.
    View in: PubMed
    Score: 0.007
  365. Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study. Nephrol Dial Transplant. 2015 Jan; 30(1):77-83.
    View in: PubMed
    Score: 0.007
  366. Fiber intake and plasminogen activator inhibitor-1 in type 2 diabetes: Look AHEAD (Action for Health in Diabetes) trial findings at baseline and year 1. J Acad Nutr Diet. 2014 Nov; 114(11):1800-10.e2.
    View in: PubMed
    Score: 0.007
  367. Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. Atherosclerosis. 2014 Oct; 236(2):251-6.
    View in: PubMed
    Score: 0.007
  368. Plasma lactate and incident hypertension in the atherosclerosis risk in communities study. Am J Hypertens. 2015 Feb; 28(2):216-24.
    View in: PubMed
    Score: 0.007
  369. Relationship of increased levels of circulating intercellular adhesion molecule 1 after heart transplantation to rejection: human leukocyte antigen mismatch and survival. J Heart Lung Transplant. 1994 Jul-Aug; 13(4):597-603.
    View in: PubMed
    Score: 0.007
  370. Validated context-dependent associations of coronary heart disease risk with genotype variation in the chromosome 9p21 region: the Atherosclerosis Risk in Communities study. Hum Genet. 2014 Sep; 133(9):1105-16.
    View in: PubMed
    Score: 0.007
  371. Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study. Arterioscler Thromb Vasc Biol. 2014 Aug; 34(8):1770-7.
    View in: PubMed
    Score: 0.007
  372. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J. 2014 Dec 07; 35(46):3277-86.
    View in: PubMed
    Score: 0.007
  373. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol. 2014 Jun; 34(6):1298-306.
    View in: PubMed
    Score: 0.007
  374. High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study. Eur Heart J. 2014 Jul 14; 35(27):1817-24.
    View in: PubMed
    Score: 0.007
  375. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 08; 370(19):1809-19.
    View in: PubMed
    Score: 0.007
  376. Analysis of multiple association studies provides evidence of an expression QTL hub in gene-gene interaction network affecting HDL cholesterol levels. PLoS One. 2014; 9(3):e92469.
    View in: PubMed
    Score: 0.007
  377. Large multiethnic Candidate Gene Study for C-reactive protein levels: identification of a novel association at CD36 in African Americans. Hum Genet. 2014 Aug; 133(8):985-95.
    View in: PubMed
    Score: 0.007
  378. Neck circumference is not associated with subclinical atherosclerosis in retired National Football League players. Clin Cardiol. 2014 Jul; 37(7):402-7.
    View in: PubMed
    Score: 0.007
  379. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol. 2014 Apr 15; 63(14):1441-8.
    View in: PubMed
    Score: 0.007
  380. Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet. 2014 Feb 06; 94(2):233-45.
    View in: PubMed
    Score: 0.007
  381. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging. 2014 Apr; 15(4):380-8.
    View in: PubMed
    Score: 0.007
  382. The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals. J Obes. 2013; 2013:729515.
    View in: PubMed
    Score: 0.006
  383. Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. Am J Respir Crit Care Med. 2013 Dec 15; 188(12):1460-5.
    View in: PubMed
    Score: 0.006
  384. Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE). Clin Biochem. 2014 Jan; 47(1-2):132-4.
    View in: PubMed
    Score: 0.006
  385. The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis. 2013 Dec; 231(2):371-7.
    View in: PubMed
    Score: 0.006
  386. APOE modulates the correlation between triglycerides, cholesterol, and CHD through pleiotropy, and gene-by-gene interactions. Genetics. 2013 Dec; 195(4):1397-405.
    View in: PubMed
    Score: 0.006
  387. Association between preoperative diuretic use and in-hospital outcomes after cardiac surgery. Cardiovasc Ther. 2013 Oct; 31(5):291-7.
    View in: PubMed
    Score: 0.006
  388. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation. 2013 Nov 26; 128(22):2395-403.
    View in: PubMed
    Score: 0.006
  389. Elevated high-sensitivity C-reactive protein as a risk marker of the attenuated relationship between serum cholesterol and cardiovascular events at older age. The ARIC Study. Am J Epidemiol. 2013 Oct 01; 178(7):1076-84.
    View in: PubMed
    Score: 0.006
  390. Correlates of repeat lipid testing in patients with coronary heart disease. JAMA Intern Med. 2013 Aug 12; 173(15):1439-44.
    View in: PubMed
    Score: 0.006
  391. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. Eur Heart J. 2013 Nov; 34(41):3182-90.
    View in: PubMed
    Score: 0.006
  392. Do genetic modifiers of high-density lipoprotein cholesterol and triglyceride levels also modify their response to a lifestyle intervention in the setting of obesity and type-2 diabetes mellitus?: The Action for Health in Diabetes (Look AHEAD) study. Circ Cardiovasc Genet. 2013 Aug; 6(4):391-9.
    View in: PubMed
    Score: 0.006
  393. The association of plasma lactate with incident cardiovascular outcomes: the ARIC Study. Am J Epidemiol. 2013 Aug 01; 178(3):401-9.
    View in: PubMed
    Score: 0.006
  394. Lipoprotein-associated phospholipase A2 and venous thromboembolism: a prospective study. Thromb Res. 2013 Jul; 132(1):44-6.
    View in: PubMed
    Score: 0.006
  395. Application of speckle-tracking in the evaluation of carotid artery function in subjects with hypertension and diabetes. J Am Soc Echocardiogr. 2013 Aug; 26(8):901-909.e1.
    View in: PubMed
    Score: 0.006
  396. NH2-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes. 2013 Sep; 62(9):3189-93.
    View in: PubMed
    Score: 0.006
  397. Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients. Med Sci Sports Exerc. 2013 Jun; 45(6):1043-50.
    View in: PubMed
    Score: 0.006
  398. Retinol binding protein 4 and incident diabetes--the Atherosclerosis Risk in Communities Study (ARIC Study). Rev Bras Epidemiol. 2013 Jun; 16(2):388-97.
    View in: PubMed
    Score: 0.006
  399. Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. J Clin Lipidol. 2013 Nov-Dec; 7(6):661-70.
    View in: PubMed
    Score: 0.006
  400. Factors underlying regression of coronary atheroma with potent statin therapy. Eur Heart J. 2013 Jun; 34(24):1818-25.
    View in: PubMed
    Score: 0.006
  401. Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. Obesity (Silver Spring). 2013 May; 21(5):944-50.
    View in: PubMed
    Score: 0.006
  402. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. J Clin Lipidol. 2013 Jul-Aug; 7(4):292-303.
    View in: PubMed
    Score: 0.006
  403. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes. 2013 Jun; 62(6):2116-21.
    View in: PubMed
    Score: 0.006
  404. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013 Feb; 13(1):37-46.
    View in: PubMed
    Score: 0.006
  405. Lactate and risk of incident diabetes in a case-cohort of the atherosclerosis risk in communities (ARIC) study. PLoS One. 2013; 8(1):e55113.
    View in: PubMed
    Score: 0.006
  406. Diabetes medication use and blood lactate level among participants with type 2 diabetes: the atherosclerosis risk in communities carotid MRI study. PLoS One. 2012; 7(12):e51237.
    View in: PubMed
    Score: 0.006
  407. Combined association of creatinine, albuminuria, and cystatin C with all-cause mortality and cardiovascular and kidney outcomes. Clin J Am Soc Nephrol. 2013 Mar; 8(3):434-42.
    View in: PubMed
    Score: 0.006
  408. Association of genome-wide variation with highly sensitive cardiac troponin-T levels in European Americans and Blacks: a meta-analysis from atherosclerosis risk in communities and cardiovascular health studies. Circ Cardiovasc Genet. 2013 Feb; 6(1):82-8.
    View in: PubMed
    Score: 0.006
  409. Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. Ann Epidemiol. 2013 Feb; 23(2):66-73.
    View in: PubMed
    Score: 0.006
  410. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Nov 29; 367(22):2089-99.
    View in: PubMed
    Score: 0.006
  411. Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. Eur J Prev Cardiol. 2014 Jul; 21(7):866-75.
    View in: PubMed
    Score: 0.006
  412. Association between statins and infections after coronary artery bypass grafting. Int J Cardiol. 2013 Sep 20; 168(1):117-20.
    View in: PubMed
    Score: 0.006
  413. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
    View in: PubMed
    Score: 0.006
  414. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol. 2012 Nov-Dec; 6(6):565-72.
    View in: PubMed
    Score: 0.006
  415. Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care. J Clin Lipidol. 2012 Nov-Dec; 6(6):545-52.
    View in: PubMed
    Score: 0.006
  416. The effect of various intensities of physical activity and chronic inflammation in men and women by diabetes status in a national sample. Diabetes Res Clin Pract. 2012 Jul; 97(1):e6-8.
    View in: PubMed
    Score: 0.006
  417. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am J Kidney Dis. 2012 May; 59(5):653-62.
    View in: PubMed
    Score: 0.006
  418. Chronic hyperglycemia and subclinical myocardial injury. J Am Coll Cardiol. 2012 Jan 31; 59(5):484-9.
    View in: PubMed
    Score: 0.006
  419. Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. Nephrol Dial Transplant. 2012 Jul; 27(7):2839-47.
    View in: PubMed
    Score: 0.006
  420. Association of gender with morbidity and mortality after isolated coronary artery bypass grafting. A propensity score matched analysis. Int J Cardiol. 2013 Jul 15; 167(1):180-4.
    View in: PubMed
    Score: 0.006
  421. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study. Circ Arrhythm Electrophysiol. 2012 Feb; 5(1):155-62.
    View in: PubMed
    Score: 0.006
  422. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects?on low-density lipoprotein-cholesterol reduction. J Clin Lipidol. 2012 Mar-Apr; 6(2):180-91.
    View in: PubMed
    Score: 0.006
  423. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011 Dec 01; 365(22):2078-87.
    View in: PubMed
    Score: 0.006
  424. Relation of lipid gene scores to longitudinal trends in lipid levels and incidence of abnormal lipid levels among individuals of European ancestry: the Atherosclerosis Risk in Communities (ARIC) study. Circ Cardiovasc Genet. 2012 Feb 01; 5(1):73-80.
    View in: PubMed
    Score: 0.006
  425. Carotid arterial wall characteristics are associated with incident ischemic stroke but not coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2012 Jan; 43(1):103-8.
    View in: PubMed
    Score: 0.006
  426. Association of variation at the ABO locus with circulating levels of soluble intercellular adhesion molecule-1, soluble P-selectin, and soluble E-selectin: a meta-analysis. Circ Cardiovasc Genet. 2011 Dec; 4(6):681-6.
    View in: PubMed
    Score: 0.006
  427. Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. Eur Heart J. 2012 Jan; 33(2):238-51.
    View in: PubMed
    Score: 0.006
  428. Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat Genet. 2011 Sep 11; 43(10):940-7.
    View in: PubMed
    Score: 0.006
  429. Segmental analysis of carotid arterial strain using speckle-tracking. J Am Soc Echocardiogr. 2011 Nov; 24(11):1276-1284.e5.
    View in: PubMed
    Score: 0.006
  430. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011 Oct 29; 378(9802):1547-59.
    View in: PubMed
    Score: 0.006
  431. Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease. Am Heart J. 2011 Oct; 162(4):725-732.e1.
    View in: PubMed
    Score: 0.006
  432. White blood cell count, C-reactive protein, and incident heart failure in the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 2011 Oct; 21(10):739-48.
    View in: PubMed
    Score: 0.005
  433. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011 Sep 01; 108(5):682-90.
    View in: PubMed
    Score: 0.005
  434. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J Clin Lipidol. 2011 Nov-Dec; 5(6):474-82.
    View in: PubMed
    Score: 0.005
  435. The editor's roundtable: JUPITER follow-up. Am J Cardiol. 2011 May 15; 107(10):1549-57.
    View in: PubMed
    Score: 0.005
  436. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. J Clin Endocrinol Metab. 2011 Jul; 96(7):2236-47.
    View in: PubMed
    Score: 0.005
  437. Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines. Am Heart J. 2011 Jun; 161(6):1140-6.
    View in: PubMed
    Score: 0.005
  438. Peripheral artery disease, biomarkers, and darapladib. Am Heart J. 2011 May; 161(5):972-8.
    View in: PubMed
    Score: 0.005
  439. Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study. Clin Chem. 2011 Jun; 57(6):891-7.
    View in: PubMed
    Score: 0.005
  440. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. Arterioscler Thromb Vasc Biol. 2011 Jul; 31(7):1689-95.
    View in: PubMed
    Score: 0.005
  441. Isolated coronary artery bypass grafting in obese individuals: a propensity matched analysis of outcomes. Circ J. 2011; 75(6):1378-85.
    View in: PubMed
    Score: 0.005
  442. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun; 5(3 Suppl):S9-17.
    View in: PubMed
    Score: 0.005
  443. Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Curr Med Res Opin. 2011 Jun; 27(6):1119-29.
    View in: PubMed
    Score: 0.005
  444. Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort. Blood. 2011 May 12; 117(19):5224-30.
    View in: PubMed
    Score: 0.005
  445. Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care. 2011 Apr; 34(4):960-7.
    View in: PubMed
    Score: 0.005
  446. Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. J Vasc Surg. 2011 Mar; 53(3):668-75.
    View in: PubMed
    Score: 0.005
  447. Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study. Int J Epidemiol. 2010 Dec; 39(6):1647-55.
    View in: PubMed
    Score: 0.005
  448. High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study. J Clin Endocrinol Metab. 2010 Nov; 95(11):5097-104.
    View in: PubMed
    Score: 0.005
  449. A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010 Nov; 33(11):2297-303.
    View in: PubMed
    Score: 0.005
  450. Carotid atherosclerosis progression in familial hypercholesterolemia patients: a pooled analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE studies. Circ Cardiovasc Imaging. 2010 Jul; 3(4):398-404.
    View in: PubMed
    Score: 0.005
  451. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010 May 01; 375(9725):1536-44.
    View in: PubMed
    Score: 0.005
  452. Intercellular adhesion molecule-1 G241R polymorphism predicts risk of incident ischemic stroke: Atherosclerosis Risk in Communities study. Stroke. 2010 May; 41(5):1038-40.
    View in: PubMed
    Score: 0.005
  453. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. Am J Cardiol. 2010 May 15; 105(10):1409-12.
    View in: PubMed
    Score: 0.005
  454. Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease. Vasc Med. 2010 Jun; 15(3):171-9.
    View in: PubMed
    Score: 0.005
  455. Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study. Arterioscler Thromb Vasc Biol. 2010 May; 30(5):1034-42.
    View in: PubMed
    Score: 0.005
  456. Safety of extended-release niacin/laropiprant in patients with dyslipidemia. J Clin Lipidol. 2010 Mar-Apr; 4(2):105-112.e1.
    View in: PubMed
    Score: 0.005
  457. Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood. 2010 Jul 01; 115(26):5289-99.
    View in: PubMed
    Score: 0.005
  458. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009 Dec; 7(6):601-10.
    View in: PubMed
    Score: 0.005
  459. Development and validation of a patient self-assessment score for diabetes risk. Ann Intern Med. 2009 Dec 01; 151(11):775-83.
    View in: PubMed
    Score: 0.005
  460. Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. BMC Med Genet. 2009 Oct 30; 10:111.
    View in: PubMed
    Score: 0.005
  461. Variation in the checkpoint kinase 2 gene is associated with type 2 diabetes in multiple populations. Acta Diabetol. 2010 Dec; 47 Suppl 1:199-207.
    View in: PubMed
    Score: 0.005
  462. Marine omega-3 fatty acid intake: associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010 Jan; 33(1):197-9.
    View in: PubMed
    Score: 0.005
  463. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. 1989 Jul 07; 262(1):53-6.
    View in: PubMed
    Score: 0.005
  464. Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost. 2009 Jul; 102(1):179-80.
    View in: PubMed
    Score: 0.005
  465. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol. 2009 Jun 15; 103(12):1694-702.
    View in: PubMed
    Score: 0.005
  466. Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). Platelets. 2009 May; 20(3):199-205.
    View in: PubMed
    Score: 0.005
  467. Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study. Circ Cardiovasc Genet. 2009 Jun; 2(3):279-85.
    View in: PubMed
    Score: 0.005
  468. Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study. J Lipid Res. 2009 Aug; 50(8):1685-91.
    View in: PubMed
    Score: 0.005
  469. Screening for kidney disease in vascular patients: SCreening for Occult REnal Disease (SCORED) experience. Nephrol Dial Transplant. 2009 Aug; 24(8):2452-7.
    View in: PubMed
    Score: 0.005
  470. The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. BMC Cardiovasc Disord. 2009 Jan 27; 9:3.
    View in: PubMed
    Score: 0.005
  471. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009 Feb 15; 103(4):515-22.
    View in: PubMed
    Score: 0.005
  472. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol. 2009 Feb 01; 103(3):369-74.
    View in: PubMed
    Score: 0.005
  473. Transcription factor 7-like 2 (TCF7L2) polymorphism and context-specific risk of type 2 diabetes in African American and Caucasian adults: the Atherosclerosis Risk in Communities study. Diabetes. 2009 Jan; 58(1):285-9.
    View in: PubMed
    Score: 0.005
  474. Association of lactate with blood pressure before and after rapid weight loss. Am J Hypertens. 2008 Dec; 21(12):1337-42.
    View in: PubMed
    Score: 0.004
  475. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008 Oct; 156(4):719-27.
    View in: PubMed
    Score: 0.004
  476. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008 Apr 29; 51(17):1632-41.
    View in: PubMed
    Score: 0.004
  477. APOE/C1/C4/C2 hepatic control region polymorphism influences plasma apoE and LDL cholesterol levels. Hum Mol Genet. 2008 Jul 01; 17(13):2039-46.
    View in: PubMed
    Score: 0.004
  478. Association of the complement factor H Y402H polymorphism with cardiovascular disease is dependent upon hypertension status: The ARIC study. Am J Hypertens. 2008 May; 21(5):533-8.
    View in: PubMed
    Score: 0.004
  479. Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Am J Cardiol. 2008 Feb 01; 101(3):401-6.
    View in: PubMed
    Score: 0.004
  480. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol. 2008 Feb 15; 101(4):490-6.
    View in: PubMed
    Score: 0.004
  481. Delayed recovery of severely "stunned" myocardium with the support of a left ventricular assist device after coronary artery bypass graft surgery. J Am Coll Cardiol. 1987 Sep; 10(3):710-2.
    View in: PubMed
    Score: 0.004
  482. Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin). Transplant Proc. 1987 Aug; 19(4 Suppl 5):60-2.
    View in: PubMed
    Score: 0.004
  483. Interaction effects of high-density lipoprotein metabolism gene variation and alcohol consumption on coronary heart disease risk: the atherosclerosis risk in communities study. J Stud Alcohol Drugs. 2007 Jul; 68(4):485-92.
    View in: PubMed
    Score: 0.004
  484. Genetic variation and decreased risk for obesity in the Atherosclerosis Risk in Communities Study. Diabetes Obes Metab. 2007 Jul; 9(4):548-57.
    View in: PubMed
    Score: 0.004
  485. Glutamic acid decarboxylase antibodies are indicators of the course, but not of the onset, of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities Study. Braz J Med Biol Res. 2007 Jul; 40(7):933-41.
    View in: PubMed
    Score: 0.004
  486. An annual, prospective, international study of outpatients with cardiovascular disease or risk factors: design and methods of the CardioMonitor registry. Crit Pathw Cardiol. 2007 Jun; 6(2):72-5.
    View in: PubMed
    Score: 0.004
  487. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol. 2007 Jun 15; 99(12):1706-1713.
    View in: PubMed
    Score: 0.004
  488. Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2007 Nov; 195(1):e76-82.
    View in: PubMed
    Score: 0.004
  489. Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis. 2008 Feb; 196(2):926-30.
    View in: PubMed
    Score: 0.004
  490. Low-density lipoprotein metabolism in cerebrotendinous xanthomatosis. Metabolism. 1987 Mar; 36(3):270-6.
    View in: PubMed
    Score: 0.004
  491. A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol. 2007 May 01; 165(9):1047-54.
    View in: PubMed
    Score: 0.004
  492. Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adults. Atherosclerosis. 2007 Oct; 194(2):e131-40.
    View in: PubMed
    Score: 0.004
  493. Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Diabetologia. 2007 Jan; 50(1):36-42.
    View in: PubMed
    Score: 0.004
  494. Pro-apoptotic low-density lipoprotein subfractions in type II diabetes. Atherosclerosis. 2007 Aug; 193(2):283-91.
    View in: PubMed
    Score: 0.004
  495. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006 Oct; 22(10):2041-53.
    View in: PubMed
    Score: 0.004
  496. Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemp Clin Trials. 2006 Dec; 27(6):518-30.
    View in: PubMed
    Score: 0.004
  497. Leptin and incident type 2 diabetes: risk or protection? Diabetologia. 2006 Sep; 49(9):2086-96.
    View in: PubMed
    Score: 0.004
  498. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006 Jul 10; 166(13):1368-73.
    View in: PubMed
    Score: 0.004
  499. Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am J Epidemiol. 2006 Aug 15; 164(4):342-8.
    View in: PubMed
    Score: 0.004
  500. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 Apr 05; 295(13):1556-65.
    View in: PubMed
    Score: 0.004
  501. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. Endocr Pract. 2006 Mar-Apr; 12(2):159-64.
    View in: PubMed
    Score: 0.004
  502. Apolipoprotein E genotype and incident ischemic stroke: the Atherosclerosis Risk in Communities Study. Stroke. 2005 Nov; 36(11):2484-6.
    View in: PubMed
    Score: 0.004
  503. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J. 2005 Dec; 26(24):2664-72.
    View in: PubMed
    Score: 0.004
  504. P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the Atherosclerosis Risk in Communities Study. Atherosclerosis. 2006 May; 186(1):74-9.
    View in: PubMed
    Score: 0.004
  505. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care. 2005 Aug; 28(8):2013-8.
    View in: PubMed
    Score: 0.004
  506. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005 May 17; 45(10):1611-9.
    View in: PubMed
    Score: 0.004
  507. Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. Am J Cardiol. 2005 Feb 01; 95(3):367-72.
    View in: PubMed
    Score: 0.003
  508. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005 Feb; 28(2):385-90.
    View in: PubMed
    Score: 0.003
  509. Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging. Magn Reson Imaging. 2004 Nov; 22(9):1249-58.
    View in: PubMed
    Score: 0.003
  510. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2004 Sep; 53(9):2473-8.
    View in: PubMed
    Score: 0.003
  511. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004 Aug; 58(8):746-55.
    View in: PubMed
    Score: 0.003
  512. Relationship between low-density lipoprotein subclasses and asymptomatic atherosclerosis in subjects from the Atherosclerosis Risk in Communities (ARIC) Study. Biomarkers. 2004 Mar-Apr; 9(2):190-202.
    View in: PubMed
    Score: 0.003
  513. Fasting plasma free fatty acids and risk of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes Care. 2004 Jan; 27(1):77-82.
    View in: PubMed
    Score: 0.003
  514. Glutathione-S-transferase genotypes, smoking, and their association with markers of inflammation, hemostasis, and endothelial function: the atherosclerosis risk in communities (ARIC) study. Atherosclerosis. 2003 Dec; 171(2):265-72.
    View in: PubMed
    Score: 0.003
  515. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2003 Jul; 52(7):1799-805.
    View in: PubMed
    Score: 0.003
  516. B vitamin status and inflammatory markers. Atherosclerosis. 2003 Jul; 169(1):169-74.
    View in: PubMed
    Score: 0.003
  517. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther. 2003 Jun; 25(6):1670-86.
    View in: PubMed
    Score: 0.003
  518. Detection of undiagnosed diabetes and other hyperglycemia states: the Atherosclerosis Risk in Communities Study. Diabetes Care. 2003 May; 26(5):1338-43.
    View in: PubMed
    Score: 0.003
  519. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation. 2003 Apr 29; 107(16):2102-8.
    View in: PubMed
    Score: 0.003
  520. Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease. Circulation. 2003 Apr 08; 107(13):1729-32.
    View in: PubMed
    Score: 0.003
  521. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2003 Mar; 34(3):623-31.
    View in: PubMed
    Score: 0.003
  522. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2003 Jan 01; 91(1):33-41.
    View in: PubMed
    Score: 0.003
  523. Platelet-monocyte complex formation: effect of blocking PSGL-1 alone, and in combination with alphaIIbbeta3 and alphaMbeta2, in coronary stenting. Thromb Res. 2003; 111(3):171-7.
    View in: PubMed
    Score: 0.003
  524. Use of denaturing HPLC to provide efficient detection of mutations causing familial hypercholesterolemia. Clin Chem. 2002 Nov; 48(11):1913-8.
    View in: PubMed
    Score: 0.003
  525. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002 Aug; 43(8):1170-80.
    View in: PubMed
    Score: 0.003
  526. LPL polymorphism predicts stroke risk in men. Genet Epidemiol. 2002 Mar; 22(3):233-42.
    View in: PubMed
    Score: 0.003
  527. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001 Sep 04; 104(10):1108-13.
    View in: PubMed
    Score: 0.003
  528. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med. 2001 Aug 15; 111(3):185-91.
    View in: PubMed
    Score: 0.003
  529. Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. Circ Res. 2001 May 11; 88(9):969-73.
    View in: PubMed
    Score: 0.003
  530. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis. 2001 Feb 15; 154(3):633-40.
    View in: PubMed
    Score: 0.003
  531. A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res. 2000 Mar 03; 86(4):391-5.
    View in: PubMed
    Score: 0.002
  532. A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. J Mol Med (Berl). 2000; 78(10):562-8.
    View in: PubMed
    Score: 0.002
  533. Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. Atherosclerosis. 1999 Jun; 144(2):435-42.
    View in: PubMed
    Score: 0.002
  534. Effect of moderate alcohol consumption on hypertriglyceridemia: a study in the fasting state. Arch Intern Med. 1999 May 10; 159(9):981-7.
    View in: PubMed
    Score: 0.002
  535. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999 Apr; 143(2):285-97.
    View in: PubMed
    Score: 0.002
  536. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997 Dec 16; 96(12):4219-25.
    View in: PubMed
    Score: 0.002
  537. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997 Aug 01; 80(3):278-86.
    View in: PubMed
    Score: 0.002
  538. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials. 1996 Dec; 17(6):550-83.
    View in: PubMed
    Score: 0.002
  539. Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. J Am Coll Cardiol. 1991 Oct; 18(4):926-30.
    View in: PubMed
    Score: 0.001
  540. Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant. Am J Cardiol. 1991 Feb 01; 67(4):243-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.